Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to CHEMOTHERAPY

Cancer Therapy Advisor

Sintilimab Provides ‘Robust’ Survival Benefit in Advanced Non-Small Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

Cancer Therapy Advisor

Neoadjuvant Nivolumab Plus Chemo Deemed New Standard Care for Resectable Non-Small Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

OBR Oncology

BMS Provides Update on CheckMate-901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma

Oncology, Medical May 25th 2022

Journal of Clinical Oncology

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

Dana-Farber Cancer Institute

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments

Obstetrics & Gynecology May 11th 2022

Journal of Clinical Oncology

Unique anti-PD-L1 plus chemotherapy improves OS vs. chemotherapy alone as 1st line in esophageal cancer

Oncology, Medical May 10th 2022